Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction

Frank Nawroth1
Andreas Tandler-Schneider2
Wilma Bilger3
1Centre for Reproductive and Prenatal Medicine, Endocrinology and Osteology, Hamburg, Germany; 2Center for Reproductive Medicine, Fertility Center Berlin, Berlin, Germany; 3Medical Affairs, Fertility, Endocrinology and General Medicine, Merck Serono GmbH, Darmstadt, Germany (an affiliate of Merck KGaA, Darmstadt, Germany)

Abstract: This prospective, noninterventional, post-marketing surveillance study evaluated doses of recombinant human follicle-stimulating hormone (r-hFSH) using the redesigned follitropin alfa pen in women who were anovulatory or oligomenorrheic and undergoing ovulation induction (OI) alone or OI with intrauterine insemination. The primary endpoint was the proportion of patients who achieved monofollicular or bifollicular development (defined as one or two follicles ≥15 mm). Secondary endpoints included characteristics of ovulation stimulation treatment, such as mean total and mean daily r-hFSH doses. Data were analyzed for 3,193 patients from 30 German fertility centers. The proportion of patients with monofollicular or bifollicular development was 71.1% (n=2,270 of a total of 3,193 patients; intent-to-treat population). The mean±standard deviation total and daily doses of r-hFSH were 696.9±542.5 IU and 61.7±29.4 IU, respectively. The three doses prescribed most frequently were: 37.5 IU (n=703 from N=3,189; 22.0%), 50.0 IU (n=1,056 from N=3,189; 33.1%), and 75.0 IU (n=738 from N=3,189; 23.1%) on the first day of stimulation; and 37.5 IU (n=465 from N=3,189; 14.6%), 50.0 IU (n=922 from N=3,189; 28.9%), and 75.0 IU (n=895 from N=3,189; 28.1%) on the last day of stimulation. This noninterventional, post-marketing surveillance study found that monofollicular or bifollicular development was achieved in 71% of patients studied and the small dose increment (12.5 IU) of the redesigned follitropin alfa pen allowed individualized treatment of women undergoing OI.

Keywords: ovulation induction, pen device, recombinant human follicle-stimulating hormone, follitropin alfa

Introduction
Gonadotropins, such as follicle-stimulating hormone (FSH), are used for ovulation induction (OI) in women with World Health Organization group II anovulatory infertility who have failed to conceive using clomifene citrate.1,2 FSH is administered during OI using low-dose protocols to stimulate the recruitment and growth of ovarian follicles. In fertility treatment cycles, the production of a single dominant follicle during ovulation is a key goal to avoid complications such as multiple pregnancies and ovarian hyperstimulation syndrome (OHSS).3,4 The benefits of FSH as a second-line therapy are evident, and the results of a study by Homburg et al also demonstrated superior reproductive outcomes after OI with low-dose FSH compared with...
clomifene citrate. They therefore concluded that FSH may be an appropriate first-line treatment for some anovulatory women, including those with polycystic ovary syndrome. Recombinant human FSH (r-hFSH; GONAL-f®; Merck Serono, Darmstadt, Germany, a subsidiary of Merck KGaA, Darmstadt, Germany) is indicated for OI in anovulatory women (including those with polycystic ovary syndrome) who have been unresponsive to clomifene citrate. r-hFSH pen devices have been developed to increase the convenience for patients when self-administering treatment.

The redesigned r-hFSH (follitropin alfa) pen (GONAL-f® prefilled pen; Merck Serono, Darmstadt, Germany) is a prefilled, ready-to-use pen designed for self-administration and has a minimum dose increment of 12.5 IU, which is smaller than for other pen devices and allows smaller dose increments to be administered. The primary objective of this study was to evaluate the doses of r-hFSH using the redesigned follitropin alfa pen, prescribed by physicians in German fertility centers for the treatment of women undergoing OI alone or with intrauterine insemination (IUI).

Materials and methods
Study design
This was a prospective, multicenter, noninterventional, post-marketing surveillance study conducted in patients undergoing OI alone or OI with IUI. Patients received treatment according to local routine practice (standard care), including measurement of developing follicles by transvaginal ultrasound. Ethical approval was obtained before commencement of the study from the Ethical Committee of the Ärztekammer Hamburg (identification number PV3951). The study was initiated on March 5, 2012 and ended on March 31, 2014.

Patients
The women included were anovulatory or oligomenorrheic and had used the redesigned follitropin alfa pen (300 IU, 450 IU, 900 IU) for OI followed by either sexual intercourse at the optimum time or IUI. Only one cycle was reported per patient. Exclusion criteria included concomitant use of other gonadotropins or clomifene citrate, and all contraindications listed in the approved prescribing information (dated May 2011) for the redesigned follitropin alfa pen (these match those listed in the current prescribing information).

Data collection
Routine pseudoanonymized clinical data were collected prospectively using the electronic RecDate ADVANCE database, which has been certified by the German in vitro fertilization registry.

Outcomes
Patient characteristics and demographics at baseline were recorded, including age, body mass index, FSH levels, antral follicle count (AFC; sum of follicles in both ovaries <11 mm in diameter in the early follicular phase), anti-Müllerian hormone, and fertility history.

Primary endpoint
The primary endpoint was the proportion of patients who achieved monofollicular or bifollicular development, ie, one or two follicles of ≥15 mm diameter at final transvaginal ultrasound assessment prior to triggering of ovulation (ideally on the day of administration of human chorionic gonadotropin but could have occurred earlier).

Secondary endpoints
The secondary endpoints evaluated included: the total number of follicles and number of follicles ≥15 mm in diameter (assessed at final transvaginal ultrasound assessment prior to triggering of ovulation); treatment characteristics (including mean daily and mean total r-hFSH dose, r-hFSH dose on first and last days of stimulation, duration of stimulation); proportions of patients according to incremental doses received on the first and last days of stimulation; and clinical pregnancy (35 days after human chorionic gonadotropin) rates per cycle. A post hoc analysis evaluated the proportion of patients according to the first dose adjustment received.

Safety
The incidences of OHSS, adverse events, and serious adverse events were recorded during the study.

Data analysis
Sample size
The sample size calculation (final analysis) was based on the response rate for monofollicular or bifollicular development as follows: using results of a multiple regression analysis, a nomogram was developed for individual doses using biomarkers for known values (eg, AFC and r-hFSH dose), with response rate for monofollicular or bifollicular development as the result. Using an alpha of 0.05, ten biomarkers/predictors, an anticipated effect size of 0.01, and statistical power of 0.9, the minimum sample size was estimated as 2,064. A larger sample size of 2,500 patients was chosen.
to allow for missing values (no formal calculation of the percentage of missing values was made).

Statistical methods
No statistical hypotheses were formulated. Absolute and relative frequencies were determined for nominal and ordinal characteristics. For quantitative variables, the median (range) and mean ± standard deviation were calculated. If appropriate, parameters were classified and also treated as ordinal characteristics. In addition, a multiple regression analysis was conducted to relate the rate of monofollicular or bifollicular development to potential biomarkers of ovarian response; data were analyzed for five baseline variables (age, body mass index, FSH levels, AFC, and anti-Müllerian hormone).

Results

Patients
Data were analyzed for 3,193 patients from 30 German in vitro fertilization centers; this was the total number of patients with complete data at study end. All patients received at least one dose of r-hFSH. Planned treatment (OI alone in 2,003 patients; OI plus IUI in 1,190 patients) was completed by 2,801 patients (1,713 of 2,003 patients receiving OI alone; 1,088 of 1,190 patients receiving OI plus IUI). Table 1 shows the patient characteristics and cause(s) of infertility. The median (range) AFC was 3.0 (0.0–34.0). Ovulation induction performed in this study was the first treatment cycle for 48.9% (1,561 of 3,193) of patients.

Follicular development data were unavailable for 372 patients. The final transvaginal ultrasound measurement of follicle size was performed on days 8–14 for most patients (n=2,005 from N=2,821; 71.1%).

Efficacy outcomes

Primary endpoint
In the intent-to-treat population, the number (%) of patients with monofollicular or bifollicular development (one or two follicles ≥15 mm) was 2,270 of 3,193 (71.1%). For the subpopulation of patients for whom data on follicular development were available (n=2,821), the proportion of patients with monofollicular or bifollicular development was 2,270 of 2,821 (80.5%).

Secondary endpoints
The mean ± standard deviation total number of follicles per patient was 3.2±4.7 and the mean ± standard deviation number of follicles ≥15 mm in diameter was 1.2±0.9.

Table I Baseline demographics and fertility characteristics of women undergoing ovulation induction using the redesigned follitropin alfa pen

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All patients (N=3,193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients’ characteristics, mean (± SD)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>32.7 (±4.8)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>24.8 (±5.6)</td>
</tr>
<tr>
<td>FSH level, IU/L</td>
<td>7.2 (±5.9)</td>
</tr>
<tr>
<td>AFC (number of follicles &lt;11 mm)</td>
<td>7.0 (±8.8)</td>
</tr>
<tr>
<td>AMH</td>
<td>4.1 (±4.3)</td>
</tr>
<tr>
<td>Fertility history, n (%)</td>
<td></td>
</tr>
<tr>
<td>Main cause of infertility</td>
<td></td>
</tr>
<tr>
<td>Both male and female infertility</td>
<td>928 (29.1)</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>499 (15.7)</td>
</tr>
<tr>
<td>Male infertility</td>
<td>467 (14.7)</td>
</tr>
<tr>
<td>Female infertility</td>
<td>1,293 (40.6)</td>
</tr>
<tr>
<td>Female infertility, n (%)</td>
<td>2,455 (76.9)</td>
</tr>
<tr>
<td>Cause of female infertility</td>
<td></td>
</tr>
<tr>
<td>Hyperandrogenemia/PCOS</td>
<td>632 (25.7)</td>
</tr>
<tr>
<td>Pathologic cycle, other endocrine disorder (not PCOS)</td>
<td>770 (31.4)</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>288 (11.7)</td>
</tr>
<tr>
<td>Other</td>
<td>1,224 (49.9)</td>
</tr>
<tr>
<td>Previous infertility treatment</td>
<td></td>
</tr>
<tr>
<td>First cycle</td>
<td>1,561 (48.9)</td>
</tr>
<tr>
<td>Second cycle</td>
<td>658 (20.6)</td>
</tr>
<tr>
<td>Third cycle</td>
<td>374 (11.7)</td>
</tr>
<tr>
<td>More than three cycles</td>
<td>600 (18.8)</td>
</tr>
</tbody>
</table>

Notes: *n=1,494; †n=2,090; ‡n=3,187; §n=2,914 causes of female infertility were reported by 2,455 patients (more than one cause could be recorded for each patient); defined as assisted reproductive technology (in vitro fertilization or intracytoplasmic sperm injection), ovulation induction, or intrauterine insemination.

Abbreviations: AFC, antral follicle count; AMH, anti-Müllerian hormone; BMI, body mass index; FSH, follicle-stimulating hormone; PCOS, polycystic ovary syndrome; SD, standard deviation.

The mean ± standard deviation duration of stimulation was 10.9±5.4 days. The mean ± standard deviation total and daily doses of r-hFSH were 696.9±542.5 IU and 61.7±29.4 IU, respectively (n=3,192).

The mean ± standard deviation daily doses of r-hFSH (n=3,189) were: 57.6±28.1 IU on the first day of stimulation and 66.5±34.5 IU on the last day of stimulation. The dose of r-hFSH received during stimulation was unchanged for most patients (n=2,003 from N=3,189; 62.8%). The mean ± standard deviation number of dose changes was 1.1±2.4; the median (range) was 0.0 (0.0–22.0).

On the first day of stimulation, 12.5 IU (lowest possible dose) was prescribed for 74 of 3,189 (2.3%) patients, and the three doses prescribed most frequently were 37.5 IU (n=703 from N=3,189; 22.0%), 50.0 IU (n=1,056 from N=3,189; 33.1%), and 75.0 IU (n=738 from N=3,189; 23.1%, Figure 1A). On the last day of stimulation, 12.5 IU was prescribed for 52 of 3,189 (1.6%) patients, and the three
doses prescribed most frequently were 37.5 IU (n=465 from N=3,189; 14.6%), 50.0 IU (n=922 from N=3,189; 28.9%), and 75.0 IU (n=895 from N=3,189; 28.1%, Figure 1B). Figure 2 shows the proportion of patients who received a 37.5, 50.0, or 75.0 IU dose on the first day of stimulation according to whether they received/did not receive a dose adjustment.

Post hoc evaluation of patients who had a dose adjustment revealed: in patients who received 37.5 IU on the first day of stimulation, the first dose adjustment was most commonly to 50.0 IU (n=190 from N=302; 62.9%) and 75.0 IU (n=102 from N=302; 33.8%); in patients who received 50.0 IU on the first day of stimulation, the first dose adjustment was most commonly to 62.5 IU (n=73 from N=363; 20.1%) and 75.0 IU (n=241 from N=363; 66.4%); in patients who received 75.0 IU on the first day of stimulation, the first dose adjustment was most commonly to 50.0 IU (n=54 from N=250; 21.6%) or 100.0 IU (n=64 from N=250; 25.6%).

Outcome data were unavailable for 862 cycles. The clinical pregnancy rate per started cycle (35 days after human chorionic gonadotropin) was 13.8% (n=441 from N=3,193). In patients for whom outcome data were available, the clinical pregnancy rate was 18.9% (n=441 from N=2,331).

Regression analysis

The multiple regression analysis for age, body mass index, FSH levels, AFC, and anti-Müllerian hormone was conducted in the subpopulation of patients for whom data on follicular development were available (n=2,821; Table 2).

Safety

There were six (n=6 from N=3,193; 0.2%) instances of OHSS; one case was grade III OHSS and required hospitalization (reported as a serious adverse event); four cases were grade I OHSS and in one case ovum pick-up was performed. Eight adverse events were reported during the study; these were early ovulation (n=1), no response (n=1), OHSS leading to hospitalization (n=1), OHSS where ovum pick-up was performed (n=1), and grade I OHSS (n=4).

Discussion

This noninterventional, post-marketing surveillance study found that monofollicular or bifollicular development was achieved in 71% of the women who received r-hFSH using the redesigned follitropin alfa pen for OI (OI alone or with IUI). The doses received by patients were generally low, with average doses on the first and last days of stimulation being about 60–70 IU. On the first day of stimulation, a low dose of r-hFSH (75 IU or lower) was received by most patients (91%); in fact, a large proportion (68%) of patients...
received a dose that was less than the approved starting
dose of 75 IU. The incidence of OHSS during the study was
low and there were only two other adverse events reported
during this study. The use of low r-hFSH doses in OI helps
to reduce the risk of OHSS.4,10 OHSS may be prevented by
using alternative methods of OI, such as laparoscopic ovarian
drilling or in vitro maturation. However, the possible risks of
alternative methods of OI should be considered and balanced
against any potential benefits.

Self-administered injection devices aim to provide a
convenient option for treatment. The redesigned follitropin
alfa pen is a ready-to-use, prefilled pen with several new
features.7 A study of patient and nurse usability factors asso-
ciated with the redesigned follitropin alfa pen using simulated
injections found that there were no unexpected operational
risks during its use and no major concerns regarding risk of
dosing errors or misuse.11

OI using a low-dose, step-up r-hFSH protocol remains
a valuable treatment option for anovulatory or oligomenor-
rhic women.12 The ability to use smaller dose increments
of r-hFSH during such protocols would provide a greater
opportunity for individualized treatment. A feature of the
redesigned follitropin alfa pen is the small 12.5 IU minimum
dose increment.7 The option of using doses lower than 75 IU
was utilized by physicians for many patients in the current
study, despite the recommended starting dose for this indica-
tion being 75–150 IU. The lowest possible single dose when
using the redesigned follitropin alfa pen, ie, 12.5 IU, was
administered in a small proportion of patients (approximately
2%) on the first and last days of stimulation at the physicians’
discretion. In addition, the 12.5 IU dose increment was used
by physicians during prescription of higher doses, for exam-
ple, 87.5 IU, and at the first dose adjustment, for example,
37.5 to 50 IU, thus allowing individualized treatment.

The multiple regression analysis conducted here did not
find any clear relationship between the rate of monofolli-
cular or bifollicular development and potential biomarkers
of ovarian response in the population studied. However,
as might be expected, there was a slight trend to suggest a
reduced rate of monofollicular or bifollicular development
with increasing age.

Study strengths include use of the RecDate database,
which provided prospective documentation of data from
approximately 18% of all fertility clinics in Germany. Possible
limitations include descriptive data evaluation and the fact that
the study was observational in nature, with no blinding and
no comparator arm. In addition, the findings of the multiple
regression analysis should be treated with caution due to the
low number of patients in the subcategories analyzed.

In summary, this noninterventional study found that
monofollicular or bifollicular development was achieved in
a large proportion of women who received r-hFSH using the
redesigned follitropin alfa pen for OI. The small dose incre-
ment (12.5 IU) of the redesigned follitropin alfa pen was
utilized by clinicians and allowed individualized treatment
of women undergoing OI.

Acknowledgments
This paper is published on behalf of the GONAL-f® Prefilled
Pen NIS group. The authors thank Elmar Beck, Anfomed,

Table 2 Results of multiple regression analysis to relate the
rate of monofollicular or bifollicular development to potential
biomarkers of ovarian response (subpopulation of patients for
whom data on follicular development were available; n=2,821)

<table>
<thead>
<tr>
<th>Baseline variable</th>
<th>n</th>
<th>Rate of mono/bifollicular development, % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age category, years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>1</td>
<td>100 (1)</td>
</tr>
<tr>
<td>20 to &lt;25</td>
<td>88</td>
<td>80.7 (71)</td>
</tr>
<tr>
<td>25 to &lt;30</td>
<td>653</td>
<td>78.9 (515)</td>
</tr>
<tr>
<td>30 to &lt;35</td>
<td>1,048</td>
<td>82.9 (869)</td>
</tr>
<tr>
<td>35 to &lt;40</td>
<td>793</td>
<td>79.6 (631)</td>
</tr>
<tr>
<td>40 to &lt;45</td>
<td>217</td>
<td>77.0 (167)</td>
</tr>
<tr>
<td>45 to &lt;50</td>
<td>21</td>
<td>76.2 (16)</td>
</tr>
<tr>
<td>BMI categorya</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>429</td>
<td>80.2 (344)</td>
</tr>
<tr>
<td>Standard weight</td>
<td>1,396</td>
<td>80.7 (1,126)</td>
</tr>
<tr>
<td>Overweight</td>
<td>526</td>
<td>79.1 (416)</td>
</tr>
<tr>
<td>Obese</td>
<td>343</td>
<td>82.2 (282)</td>
</tr>
<tr>
<td>Morbidly obese</td>
<td>75</td>
<td>80.0 (60)</td>
</tr>
<tr>
<td>FSH category, IU/L3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2.5</td>
<td>73</td>
<td>76.7 (56)</td>
</tr>
<tr>
<td>2.5 to &lt;10.2</td>
<td>1,193</td>
<td>78.2 (933)</td>
</tr>
<tr>
<td>≥10.2</td>
<td>141</td>
<td>76.6 (108)</td>
</tr>
<tr>
<td>AFC categoryc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>401</td>
<td>85.3 (342)</td>
</tr>
<tr>
<td>1 to 5</td>
<td>624</td>
<td>80.0 (499)</td>
</tr>
<tr>
<td>6 to 10</td>
<td>275</td>
<td>76.4 (210)</td>
</tr>
<tr>
<td>11 to 15</td>
<td>157</td>
<td>80.9 (127)</td>
</tr>
<tr>
<td>&gt;15</td>
<td>328</td>
<td>79.9 (262)</td>
</tr>
<tr>
<td>AMH category, ng/mLd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>162</td>
<td>73.5 (119)</td>
</tr>
<tr>
<td>1 to &lt;5</td>
<td>599</td>
<td>77.5 (464)</td>
</tr>
<tr>
<td>5 to &lt;10</td>
<td>201</td>
<td>76.1 (153)</td>
</tr>
<tr>
<td>≥10</td>
<td>80</td>
<td>78.8 (63)</td>
</tr>
</tbody>
</table>

Notes: BMI was measured in kg/m²; categories were defined as follows: underweight
<20, standard weight 20 to <25, overweight 25 to <30, obese 30 to <40, morbidly
obese ≥40; FSH data were available for 1,407 patients for whom data on follicular
development were available; AFC data were available for 1,785 patients for whom
data on follicular development were available; AMH data were available for 1,042 patients for whom
data on follicular development were available.

Abbreviations: AFC, antral follicle count; AMH, anti-Müllerian hormone;
BMI, body mass index; FSH, follicle-stimulating hormone.

| Study strengths include use of the RecDate database, which provided prospective documentation of data from approximately 18% of all fertility clinics in Germany. Possible limitations include descriptive data evaluation and the fact that the study was observational in nature, with no blinding and no comparator arm. In addition, the findings of the multiple regression analysis should be treated with caution due to the low number of patients in the subcategories analyzed. |
Germany, for statistical support, and Jocelyn Woodcock of Caudex Medical, Oxford, UK (supported by Merck KGaA, Darmstadt, Germany) for her assistance with preparation of this paper. The statistical analysis was performed by Anfomed.

Author contributions
All authors contributed to drafting of the manuscript and critical discussions, and approved the manuscript before submission for publication. FN, WB, and the sponsor contributed to the study design. All authors and the sponsor were involved in data interpretation. The sponsor collected the data and all authors had full access to data.

Disclosure
This study was sponsored by Merck KGaA, Darmstadt, Germany. WB is an employee of Merck Serono GmbH, Germany. FN and AT-S report no conflicts of interest in this work.

References